MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'cipro'. Sat, 03 Sep 2011 02:38:21 +0100 http://www.medworm.com/index.php?rid=4560598&cid=t_140507_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FDDJwXnTTp4M%2F The Supreme Court rejected a challenge to a pay-to-delay deal in which Bayer paid Barr Pharmaceuticals, which is now owned by Teva Pharmaceuticals, to drop a patent lawsuit over the Cipro antibiotic (see this). The move is a blow to the Federal Trade Commission, which calls the deals anticompetitive and had been hoping the Supreme Court would review a case in the face of legislative inactivity. The issue has divided lower courts around the country for years. A wholesaler and three retailers, including CVS and Rite-Aid, asked the Supreme Court to review the settlement, arguing the deals choke off competition by stifling the arrival of lower-cost generics on their shelves. In the case they cited, Barr challenged the Cipro patent in October 1991 and struck a deal with Bayer in January 1997 tw... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4560598 Mon, 07 Mar 2011 22:44:07 +0100 4560598 http://www.medworm.com/index.php?rid=4331236&cid=t_140507_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FED0DYDEIm1U%2F The controversy over so-called pay-to-delay settlements between brand-name and generic drugmakers has prompted attorneys general from 32 states to file an amicus, or friend-of-the-court brief urging the US Supreme Court to review the deals, which the states say thwart competition and block needed access to lower-cost medications. The move comes less than a month after three pharmacy chains and a wholesaler petitioned the court to rule on the issue, which has divided other federal courts (see this) and spurred the Federal Trade Commission into a Quixotic quest to urge Congress to pass a law to restrict these deals (back story). The case that precipitated these filings involved a deal in which Bayer paid Barr Pharmaceuticals, which is now owned by Teva Pharmaceuticals, to drop its patent cha... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4331236 Tue, 11 Jan 2011 13:26:37 +0100 4331236 http://www.medworm.com/index.php?rid=4272601&cid=t_140507_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FpAmBhLecykw%2F The controversy over the so-called pay-to-delay settlements is bubbling up to the US Supreme Court. Three pharmacy chains and a wholesaler have asked the court to review the issue because they maintain the deals choke off competition by stifling the arrival of lower-cost generics on their shelves. The issue has become a cause celebre for the US Federal Trade Commission (look here), which has been lobbying Congress to enact legislation to restrict the settlements, and has also divided courts across the country, which is why the Supreme Court was asked to review the topic and settle the matter. The case cited by the retailers and wholesaler involved a deal in which Bayer paid Barr Pharmaceuticals, which is now owned by Teva Pharmaceuticals, to drop its patent challenge to the Cipro antibiot... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4272601 Mon, 20 Dec 2010 15:41:59 +0100 4272601 http://www.medworm.com/index.php?rid=4023122&cid=t_140507_150_f&fid=34768&url=http%3A%2F%2Fpharmagossip.blogspot.com%2F2010%2F10%2Fps-from-john-fratti-about.html John's original letter to PharmaGossip: http://pharmagossip.blogspot.com/2010/10/ex-drug-rep-writes.htmlHere's the ps:We have started a Facebook site for fluoroquinolone antibiotic toxicity and have a petition with close to 300 signatures. It is a petition for a Black Box warning for severe disabling central nervous system disorders. Here is the link: http://www.facebook.com/pages/Fluoroquinolone-Antibiotic-Toxicity-Cipro-Levaquin-Avelox-Floxin/106912045999263?v=app_6009294086&ref=ts (Source: PharmaGossip) PharmaGossip blogs http://www.medworm.com/rss/comments.php?id=4023122 Fri, 01 Oct 2010 16:43:00 +0100 4023122 http://www.medworm.com/index.php?rid=3946687&cid=t_140507_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FT2IYaC17BMc%2F In yet another blow to the US Federal Trade Commission, a federal appeals court has refused to reconsider its ruling last April that upheld the legality of so-called pay-for-delay deals that thwart the introduction of generic rivals (here is the order). However, in a dissenting opinion, Justice Rosemary Pooler writes that the issue must ultimately be decided by the US Supreme Court, given the conflicting outcomes in various cases. The initial ruling by the US Second Circuit Court of Appeals was made after reviewing a deal in which Bayer paid Barr Pharmaceuticals, which is now owned by Teva Pharmaceuticals, to drop its patent challenge to the Cipro antibiotic. Barr challenged the Cipro patent in October 1991 and struck a deal with Bayer in January 1997, about two weeks before the case was s... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3946687 Wed, 08 Sep 2010 12:03:05 +0100 3946687 http://www.medworm.com/index.php?rid=3577626&cid=t_140507_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2Fh_IpIo82H4Y%2F A federal appeals court last month may have upheld the legality of pay-for-delay deals that thwart the introduction of generics, but the issue isn’t dead yet. A group of consumers, union health and welfare funds, which have been certified as a class, are asking a California appeals court to review the same set of circumstances involving Bayer, Barr Pharmaceuticals and the Cipro antibiotic. At issue in both cases is a deal in which Bayer paid Barr, now owed by Teva Pharmaceuticals, to drop its 1991 patent challenge to Cipro. In 1997, Barr struck a deal with Bayer just two weeks before a lawsuit was set to go to trial, delaying the entrance of a generic version. The US Second Circuirt Court of Appeals ruled the deal was kosher (see here), although the Federal Trade Commission continues... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3577626 Wed, 19 May 2010 12:11:47 +0100 3577626 http://www.medworm.com/index.php?rid=3519709&cid=t_140507_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FLrxAf4BduMM%2F In a blow to the Federal Trade Commission, the US Second Circuirt Court of Appeals has upheld the legality of so-called pay-for-delay deals that thwart the introduction of generic rivals. But at the same time, the court suggested the issue needed further review (see the ruling). The ruling was made after reviewing a deal in which Bayer paid Barr Pharmaceuticals, which is now owed by Teva Pharmaceuticals, to drop its patent challenge to the Cipro antibiotic. Barr challenged the Cipro patent in October 1991 and struck a deal with Bayer in January 1997, about two weeks before the case was set to go to trial. The ruling is yet another setback for the Federal Trade Commission, which has been pushing aggressively to end pay-to-delay deals (look here). Two months ago, a federal judge dismissed an... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3519709 Fri, 30 Apr 2010 12:17:52 +0100 3519709 http://www.medworm.com/index.php?rid=2630329&cid=t_140507_135_f&fid=35274&url=http%3A%2F%2Facidrefluxweb.com%2F%3Fp%3D3834 There is nothing off limits for me. Some have been critical that I highlight some of the not so pleasant results of one’s immune system being in a daily state of war, taking medications, and all the other glamorous stuff that goes along with it. To them I say, this is life — sometimes it’s not pretty. And what a perfect way to segue into this little story. For weeks, I was having some troubles that I had attributed to recent spade of numerous rounds of antibiotics needed for mostly the ongoing saga that resulted in my one tooth removed, and in my mind, one step closer to being homeless (don’t homeless people have teeth missing?). I tried my best to not be an hypochondriac, trust me, it’s easy to turn into. My mother is one, so it runs in the family. But I knew... acidrefluxweb.com blogs http://www.medworm.com/rss/comments.php?id=2630329 Wed, 22 Jul 2009 18:05:17 +0100 2630329 http://www.medworm.com/index.php?rid=2591665&cid=t_140507_135_f&fid=35274&url=http%3A%2F%2Facidrefluxweb.com%2F%3Fp%3D3786 Yap. That’s what you get when you wake up in the morning to find that the freezer door had not shut properly. At first I checked the contents out, and they were only a little bit unfrozen. Having just stocked up on a shitload of chicken on sale, the cheap side my brain kicked in. This is probably the side that I inherited from my very cheap father. I’m still suffering from the fact for my first bike he bought for me as a child was a girls bike. “There’s nothing wrong with it?” he’d say to me. It’s amazing what you can gloss over when saving money is concerned. And this I did. “How bad can it be?” I thought as I slammed the freezer shut. That was until last weekend when I cooked some up – Shake an Bake, to be exact – that I realized a day or two later that just as bad ... acidrefluxweb.com blogs http://www.medworm.com/rss/comments.php?id=2591665 Sat, 11 Jul 2009 04:11:08 +0100 2591665 http://www.medworm.com/index.php?rid=1603098&cid=t_140507_97_f&fid=35050&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmaGazette%2F%7E3%2F331021305%2Ffluroquinolone_antimicrobial_d.html The U.S Food and Drug Administration has notified the manufacturers of fluroquinolone antimicrobial drugs that a "boxed warning" in the label of the product is required to inform patients of the increased risk of tendonitis and tendon rupture.Aside from the boxed warning the FDA also decided that manufactures provide a Medication Guide to patients warning of the possible side effects. The drugs already carry a warning of an increased risk of tendon ruptures but an increased number of adverse event reports prompted the increased visibility of that warning.The class of antimicrobial drugs known as fluroquinolones, such as Cipro, have been approved to treat or prevent bacterial infections such as sinusitus, urinary tract infections, cystitis and lower respiratory tract infections.Th... PharmaGazette blogs http://www.medworm.com/rss/comments.php?id=1603098 Wed, 09 Jul 2008 19:00:33 +0100 1603098 http://www.medworm.com/index.php?rid=1128855&cid=t_140507_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F210779138%2F The consumer group went to federal court today to force the agency to act on a petition filed last summer seeking stronger warnings about the risks of tendon rupture associated with fluroquinolones, a class of antibiotics used to treat bacterial infections. These includes Levaquin, a Johnson & Johnson med, and Bayer’s Cipro, along with other brand name versions and various generics. (Here is the lawsuit). Although the labels warn of tendon ruptures, Public Citizen wants the FDA to place Black Box warnings on the drugs. J&J has said it believes the current tendon warning is adequate while Schering-Plough, which markets Cipro in the US as part of an agreement with Bayer, has said it won’t comment on Public Citizen’s petition, according to Dow Jones. The consumer g... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1128855 Thu, 03 Jan 2008 19:50:28 +0100 1128855 http://www.medworm.com/index.php?rid=804516&cid=t_140507_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F145150355%2F First, Johnson & Johnson sues the American Red Cross over the red cross trademark. Now, the German drugmaker is suing a hospital in Ontario, Canada, for allegedlly duplicating its Cipro antibiotic and selling a more concentrated, generic version. This may be another no-win situation for a big pharma, but clearly, suing a hospital trying to serve patients doesn’t look good. “I think this is going to look, from Bayer’s point of view, pretty petty,” Joel Lexchin, an emergency doctor and health policy professor at Toronto’s York University, tells The National Post. “The hospital is probably doing this for a small number of patients, costing Bayer almost zilch in terms of lost sales. If this drives up hospital costs, Bayer, I don’t think, would loo... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=804516 Fri, 17 Aug 2007 12:54:36 +0100 804516